Bremelanotide (PT-141)

Bremelanotide is a laboratory-produced peptide originating from work on Melanotan II. It has been investigated in relation to sexual desire and arousal, including research involving women and men.

Melanocortin signaling participates in nervous-system processes relevant to sexual responses. The guide places bremelanotide within this biological context and characterizes its approach as distinct from hormone replacement.

The proposed mechanism centers on stimulation of melanocortin receptors and associated neural signaling. The guide also lists blood-vessel dilation, but the supplied material does not establish whether this is a direct mechanism or a secondary physiological effect.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 03 · Early human research

Small or early-stage human studies exist, with limited certainty and reproducibility.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source portrays bremelanotide as a Melanotan II-related compound explored for potential effects on sexual responses in both sexes. It presents increased desire and improved sexual performance as potential benefits, without supplying study details that would substantiate these claims. The guide offers a favorable tolerability assessment while acknowledging nausea, head pain, and skin flushing.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The extracted material does not establish the strength, consistency, or population-specific applicability of the reported benefits. Its vascular explanation and broad characterization of tolerability require verification against primary clinical evidence.

Reported adverse effects include nausea, headache, and flushing; their frequency and severity cannot be determined from these notes. Safety data are limited in the supplied material, so its reassuring characterization should not be treated as a comprehensive risk assessment. This summary is not medical advice, and individual safety concerns warrant discussion with a qualified healthcare professional.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Bremelanotide PT-141 sexual dysfunction clinical trial”
• “Efficacy of Bremelanotide in HSDD”
• “PT-141 peptide for sexual arousal”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN